Biotech startups in New York City
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Pathos | New York | Series E | $237.0M | 2026-10-23 |
| Evvy | New York | Series B | $40.0M | 2026-09-15 |
| Massive Bio | New York | Series B | $17.0M | 2022-06-02 |
| Gameto | New York | Series C | $44.0M | 2025-08-12 |
| Waypoint Bio | New York | Series A | $20.0M | 2026-05-27 |
| Glyphic Biotechnologies | New York | Series A | $38.0M | 2025-09-26 |
| Gilgamesh Pharmaceuticals | New York | Series A | $60.0M | 2026-03-24 |
| Levels | New York | Series A | $10.0M | 2024-08-14 |
8 rows of the CSV in 5 of its 18 columns.
- The 263 biotech startups in New York City have raised $9.4B in total.
- 42 of them closed their most recent round in the last 12 months, $1.2B combined.
- The largest of those rounds is Pathos' $237.0M Series E, dated October 2026.
- SOSV SF & NY (Fka IndieBio) is an investor in 6 of them, more than any other fund.
- Health care is the most common other sector, with 206 companies (78%).
- 41% were founded in 2020 or later; the median founding year is 2019.
- The most common team size is 1 to 10 employees (48% of companies with a recorded size).
- 2 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
23 of 263| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Pathos | Pathos is a biotechnology company that uses AI to speed up oncology drug development. | Artificial intelligence | Series E | $237.0M | 2026-10-23 | $684.0M | New Enterprise Associates, Lightbank, Builders VC +1 | 11 to 50 | 2022 |
| Evvy | Evvy offers an AI-driven precision medicine platform focused on women's health. | Artificial intelligence | Series B | $40.0M | 2026-09-15 | $59.0M | General Catalyst, BoxGroup, Left Lane Capital +2 | 11 to 50 | 2021 |
| heXem bio | HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells and extend healthy lifespan. | Biotech | Seed | $10.4M | 2026-09-15 | $10.4M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| ElectroKare | ElectroKare builds computational models that simulate human physiological systems and processes. | Artificial intelligence | Seed | $4.0M | 2026-07-01 | $4.0M | iVenture Accelerator, Techstars Physical Health, Fort Worth, Texas | 11 to 50 | 2025 |
| Kimba | Kimba uses AI to analyze biometric data and deliver personalized scent treatments for better sleep and health. | Artificial intelligence | Seed | $5.4M | 2026-06-16 | $6.4M | Techstars | 1 to 10 | 2024 |
| Waypoint Bio | Waypoint Bio applies spatial biology to improve cell therapy development. | Artificial intelligence | Series A | $20.0M | 2026-05-27 | $34.5M | Village Global, Fifty Years, Hummingbird Ventures +2 | 11 to 50 | 2021 |
| Century Health | Century Health applies AI to real-world clinical data to accelerate drug development and commercialization. | Artificial intelligence | Seed | $5.0M | 2026-05-19 | $7.0M | Alumni Ventures, Everywhere Ventures, 2048 Ventures +1 | 1 to 10 | 2023 |
| Click Therapeutics | Click Therapeutics develops and commercializes software-based prescription treatments for unmet healthcare needs. | Biotech | Series D | $50.0M | 2026-04-09 | $1.1B | Silicon Valley Bank, Accelmed, HSBC Innovation Banking +1 | 101 to 250 | 2012 |
| Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic drugs to treat mental illness. | Biotech | Series A | $60.0M | 2026-03-24 | $142.6M | Y Combinator, Alumni Ventures, Gaingels +2 | 11 to 50 | 2019 |
| OncoPrecision | OncoPrecision develops patient-centric therapeutic antibodies. | Biotech | Seed | $4.5M | 2025-11-24 | $11.1M | SOSV, SOSV SF & NY (Fka IndieBio), GRID EXPONENTIAL +2 | 11 to 50 | 2020 |
| Helex | Helex works on making gene editing safer. | Biotech | Seed | $3.5M | 2025-10-30 | $4.6M | SOSV, SOSV SF & NY (Fka IndieBio) | 11 to 50 | 2021 |
| Gameto | Gameto develops cell-engineered therapeutics for the female reproductive system. | Biotech | Series C | $44.0M | 2025-08-12 | $117.0M | FJ Labs, Insight Partners, Gaingels +2 | 11 to 50 | 2020 |
| Argon AI | Argon AI automates life sciences activities in clinical and commercial settings. | Artificial intelligence | Seed | $5.5M | 2025-07-02 | $11.5M | Y Combinator, Pioneer Fund, Eight Capital | 1 to 10 | 2023 |
| TMRW Life Sciences | TMRW Life Sciences manages cryospecimens with automated, software-guided platforms. | Biotech | Series D | $28.2M | 2024-07-12 | $181.7M | Google Ventures, Casdin Capital, 5AM Ventures | 51 to 100 | 2018 |
| Formation Bio Unicorn | Formation Bio is a drug development company that aims to speed treatments to patients by reimagining clinical trials. | Artificial intelligence | Series D | $372.0M | 2024-06-26 | $528.0M | Andreessen Horowitz, Sequoia Capital, Thrive Capital +1 | 101 to 250 | 2013 |
| EvolutionaryScale | EvolutionaryScale develops biological AI models for therapeutic design. | Artificial intelligence | Seed | $142.0M | 2024-06-25 | $142.0M | Lux Capital, NVentures | 11 to 50 | 2023 |
| Carez AI | Carez AI builds vision models designed to perform reliably in real-world conditions. | Artificial intelligence | Pre-seed | $150K | 2024-01-08 | $150K | (ERA) Entrepreneurs Roundtable Accelerator | 1 to 10 | 2024 |
| Native AI | Native AI provides an always-on market intelligence platform for understanding customers and creating better experiences. | Artificial intelligence | Seed | $3.5M | 2023-04-06 | $5.7M | Capital Innovators, Connetic Ventures, IvyCap Ventures +2 | 11 to 50 | 2018 |
| Massive Bio | Massive Bio runs an AI oncology platform that matches patients with clinical trials and gives pharma companies access to them. | Artificial intelligence | Series B | $17.0M | 2022-06-02 | $23.8M | 500 Global, 500 Emerging Europe, KFW DEG | 101 to 250 | 2015 |
| Immunai Unicorn | Immunai applies machine learning and software engineering to map and reprogram immunology. | Artificial intelligence | Series B | $215.0M | 2021-10-27 | $295.0M | 8VC, TLV Partners, Alexandria Venture Investments +2 | 101 to 250 | 2018 |
| Flextrapower | Flextrapower is a remote-monitoring company powered by graphene technology. | Biotech | Seed | $120K | 2019-07-15 | $1.2M | Techstars, MassChallenge, National Science Foundation +2 | 11 to 50 | 2015 |
| Pymetrics | Pymetrics develops neuroscience-based assessment technology that predicts candidate fit for staffing firms. | Artificial intelligence | Series B | $40.0M | 2018-09-27 | $56.6M | MassChallenge, Khosla Ventures, Salesforce Ventures +2 | 101 to 250 | 2011 |
| Zpoken AI | Zpoken AI is a data science company focused on cognitive solutions. | Artificial intelligence | Seed | $130K | 2017-02-01 | $130K | Starta VC, Starta Accelerator | 11 to 50 | 2016 |
Table 1. Biotech startups in New York City: the 23 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 263.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pathos | Pathos is a biotechnology company that uses AI to speed up oncology drug development. | Artificial intelligence | Series E | $237.0M | 2026-10-23 | $684.0M | New Enterprise Associates, Lightbank, Builders VC +1 | 11 to 50 | 2022 |
| 2 | Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing psychedelic drugs to treat mental illness. | Biotech | Series A | $60.0M | 2026-03-24 | $142.6M | Y Combinator, Alumni Ventures, Gaingels +2 | 11 to 50 | 2019 |
| 3 | Click Therapeutics | Click Therapeutics develops and commercializes software-based prescription treatments for unmet healthcare needs. | Biotech | Series D | $50.0M | 2026-04-09 | $1.1B | Silicon Valley Bank, Accelmed, HSBC Innovation Banking +1 | 101 to 250 | 2012 |
| 4 | Evvy | Evvy offers an AI-driven precision medicine platform focused on women's health. | Artificial intelligence | Series B | $40.0M | 2026-09-15 | $59.0M | General Catalyst, BoxGroup, Left Lane Capital +2 | 11 to 50 | 2021 |
| 5 | Waypoint Bio | Waypoint Bio applies spatial biology to improve cell therapy development. | Artificial intelligence | Series A | $20.0M | 2026-05-27 | $34.5M | Village Global, Fifty Years, Hummingbird Ventures +2 | 11 to 50 | 2021 |
| 6 | heXem bio | HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells and extend healthy lifespan. | Biotech | Seed | $10.4M | 2026-09-15 | $10.4M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| 7 | Kimba | Kimba uses AI to analyze biometric data and deliver personalized scent treatments for better sleep and health. | Artificial intelligence | Seed | $5.4M | 2026-06-16 | $6.4M | Techstars | 1 to 10 | 2024 |
| 8 | Century Health | Century Health applies AI to real-world clinical data to accelerate drug development and commercialization. | Artificial intelligence | Seed | $5.0M | 2026-05-19 | $7.0M | Alumni Ventures, Everywhere Ventures, 2048 Ventures +1 | 1 to 10 | 2023 |
| 9 | OncoPrecision | OncoPrecision develops patient-centric therapeutic antibodies. | Biotech | Seed | $4.5M | 2025-11-24 | $11.1M | SOSV, SOSV SF & NY (Fka IndieBio), GRID EXPONENTIAL +2 | 11 to 50 | 2020 |
| 10 | ElectroKare | ElectroKare builds computational models that simulate human physiological systems and processes. | Artificial intelligence | Seed | $4.0M | 2026-07-01 | $4.0M | iVenture Accelerator, Techstars Physical Health, Fort Worth, Texas | 11 to 50 | 2025 |
Table 2. Biotech startups in New York City: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | SOSV SF & NY (Fka IndieBio) | Venture capital firm | San Francisco, United States | 6 | 2% | 2 | heXem bio, OncoPrecision |
| 2 | SOSV | Venture capital firm | Princeton, United States | 6 | 2% | 2 | heXem bio, OncoPrecision |
| 3 | Alumni Ventures | Angel group | Manchester, United States | 5 | 2% | 2 | Century Health, Gilgamesh Pharmaceuticals |
| 4 | Y Combinator | Startup accelerator | Mountain View, United States | 4 | 2% | 1 | Gilgamesh Pharmaceuticals |
| 5 | Catalio Capital Management | Venture capital firm | New York, United States | 4 | 2% | ||
| 6 | Gaingels | Syndicate | Burlington, United States | 3 | 1% | 1 | Gilgamesh Pharmaceuticals |
| 7 | Pioneer Fund | Startup accelerator | Toronto, Canada | 3 | 1% | 1 | Gilgamesh Pharmaceuticals |
| 8 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 3 | 1% | ||
| 9 | BoxGroup | Venture capital firm | New York, United States | 2 | 1% | 1 | Evvy |
| 10 | RA Capital Management | Startup incubator | Boston, United States | 2 | 1% | ||
| 11 | National Institutes of Health | Entrepreneurship program | Bethesda, United States | 2 | 1% | ||
| 12 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 2 | 1% | ||
| 13 | Polaris Partners | Private equity firm | Boston, United States | 2 | 1% | ||
| 14 | MassChallenge | Startup accelerator | Boston, United States | 2 | 1% | ||
| 15 | Techstars | Startup accelerator | New York, United States | 2 | 1% | 1 | Kimba |
Table 3. Biotech startups in New York City: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 206 | 78% | $8.9B |
| Software | 75 | 29% | $3.2B |
| Artificial intelligence | 61 | 23% | $2.6B |
| Hardware | 10 | 4% | $94.3M |
| Fintech | 8 | 3% | $15.8M |
| Education | 4 | 2% | $78.4M |
| Cybersecurity | 3 | 1% | $31.2M |
| Energy | 2 | 1% | $6.8M |
| Commerce | 1 | 0% |
Table 4. Biotech startups in New York City by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in New York City by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 3 | 7% | $241.0M |
| September 2026 | 5 | 12% | $132.5M |
| August 2026 | 2 | 5% | $3.5M |
| July 2026 | 2 | 5% | $5.5M |
| June 2026 | 2 | 5% | $5.5M |
| May 2026 | 5 | 12% | $79.0M |
| April 2026 | 3 | 7% | $97.0M |
| March 2026 | 3 | 7% | $110.0M |
| February 2026 | 1 | 2% | $115.0M |
| January 2026 | 6 | 14% | $237.5M |
| December 2025 | 7 | 17% | $151.8M |
| November 2025 | 3 | 7% | $4.5M |
Table 6. Biotech startups in New York City: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 32 | 12% | $1.0B |
| 2025 | 41 | 16% | $681.5M |
| 2024 | 25 | 10% | $1.1B |
| 2023 | 25 | 10% | $353.6M |
| 2022 | 25 | 10% | $147.0M |
| 2021 | 40 | 15% | $1.3B |
Table 7. Biotech startups in New York City by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 46 | 18% |
| 2020 to 2022 | 58 | 23% |
| 2015 to 2019 | 94 | 37% |
| 2010 to 2014 | 38 | 15% |
| Before 2010 | 18 | 7% |
Table 8. Biotech startups in New York City by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 125 | 48% |
| 11 to 50 | 104 | 40% |
| 51 to 100 | 12 | 5% |
| 101 to 250 | 11 | 4% |
| 251 to 500 | 3 | 1% |
| 1,001 to 5,000 | 2 | 1% |
| 5,001 to 10,000 | 1 | 0% |
Table 9. Biotech startups in New York City by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in New York City. On 16 November 2026 that is 263 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 23 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 263 rows: 87 have no round amount, 0 no city and 43 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in New York City are on the list?
- 263, in the file dated 16 November 2026. 42 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 263 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.